cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5281/zenodo.5819123
title: Elevated C-reactive protein levels across diagnoses: The first comparison among inpatients with major depressive disorder, bipolar disorder, or obsessive–compulsive disorder

description: Elevated C-reactive protein levels across diagnoses: The first comparison among inpatients with major depressive disorder, bipolar disorder, or obsessive–compulsive disorder Objective: We addressed elevated C-reactive protein level (eCRP) specificity comparing, for the first time, eCRP (i.e., serum CRP &gt; 3 and ≤10 mg/L) in patients with major depressive disorder (MDD), bipolar disorder (BD), or obsessive–compulsive disorder (OCD). We also assessed to what extent multiple variables that can potentially increase inflammation may have influenced eCRP in our sample.<br> Methods: We performed a retrospective, observational, cross-sectional study using information documented in the electronic medical records (EMRs) of patients hospitalized for a 4-week psychiatric rehabilitation program. We collected all information according to the standardized procedures of the hospital’s clinical practice and applied a logistic regression model (α = 0.05).<br> Results: We included 388 inpatients, that is, 156 (40.2%) with MDD, 135 (34.8%) with BD, and 97 (25.0%) with OCD, and found considerable eCRP rates among them (36.5%, 47.4%, and 29.9% in MDD, BD, and OCD, respectively) but without significant differences across groups. In the whole sample, eCRP variations were only partially attributable (approximately for one-third) to potential confounders. All groups presented considerable rates of cardiovascular risk factors, and we classified most patients as having medium or high CRP-based cardiovascular risk.<br> Conclusion: This first study comparing eCRP in MDD, BD, and OCD suggests that eCRP may be a transdiagnostic feature of different psychiatric disorders, and other mechanisms beyond the effects of multiple confounders may explain the presence of eCRP in a substantial portion of psychiatric patients. Therefore, we encourage the routine measurement of CRP in psychiatric clinical practice.
DOI: 10.5281/zenodo.5819122
title: Elevated C-reactive protein levels across diagnoses: The first comparison among inpatients with major depressive disorder, bipolar disorder, or obsessive–compulsive disorder

description: Elevated C-reactive protein levels across diagnoses: The first comparison among inpatients with major depressive disorder, bipolar disorder, or obsessive–compulsive disorder Objective: We addressed elevated C-reactive protein level (eCRP) specificity comparing, for the first time, eCRP (i.e., serum CRP &gt; 3 and ≤10 mg/L) in patients with major depressive disorder (MDD), bipolar disorder (BD), or obsessive–compulsive disorder (OCD). We also assessed to what extent multiple variables that can potentially increase inflammation may have influenced eCRP in our sample.<br> Methods: We performed a retrospective, observational, cross-sectional study using information documented in the electronic medical records (EMRs) of patients hospitalized for a 4-week psychiatric rehabilitation program. We collected all information according to the standardized procedures of the hospital’s clinical practice and applied a logistic regression model (α = 0.05).<br> Results: We included 388 inpatients, that is, 156 (40.2%) with MDD, 135 (34.8%) with BD, and 97 (25.0%) with OCD, and found considerable eCRP rates among them (36.5%, 47.4%, and 29.9% in MDD, BD, and OCD, respectively) but without significant differences across groups. In the whole sample, eCRP variations were only partially attributable (approximately for one-third) to potential confounders. All groups presented considerable rates of cardiovascular risk factors, and we classified most patients as having medium or high CRP-based cardiovascular risk.<br> Conclusion: This first study comparing eCRP in MDD, BD, and OCD suggests that eCRP may be a transdiagnostic feature of different psychiatric disorders, and other mechanisms beyond the effects of multiple confounders may explain the presence of eCRP in a substantial portion of psychiatric patients. Therefore, we encourage the routine measurement of CRP in psychiatric clinical practice.
DOI: 10.5281/zenodo.5819129
title: Alexithymia, resilience, somatic sensations and their relationships with suicide ideation in drug naïve patients with first-episode major depression: An exploratory study in the "real world" everyday clinical practice

description: Alexithymia, resilience, somatic sensations and their<br> relationships with suicide ideation in drug naïve patients<br> with first-episode major depression: An exploratory study<br> in the “real world” everyday clinical practice Aim: The present study is aimed at revaluating alexithymia, somatic sensations, resilience<br> and their relationships with suicide ideation in drug naïve adult outpatients suffering<br> from first episode major depression (MD).<br> Methods: Data of 103 adult outpatients (49 men, 56 women) with a diagnostic and<br> statistical manual of mental disorders, 4th edition, text revision (DSM-IV-TR) diagnosis<br> of MD were analysed. Alexithymia was measured using the 20-item Toronto<br> Alexithymia Scale (TAS-20) and resilience with the 25 items Connor-Davidson Resilience<br> Scale (CD-RISC) whereas depression was evaluated using the 17-item Hamilton<br> Depression Rating Scale, somatic sensations with the Body Sensations Questionnaire<br> and suicide ideation with Scale of Suicide Ideation (SSI). Results: Gender comparisons between all demographic and clinical variables showed<br> no significant differences in all variables. Subjects who were found positive for<br> alexithymia showed higher scores on all clinical variables controlling for age, gender<br> and duration of the current episode. In a linear regression model, lower scores on<br> CD-RISC and Difficulty in Identifying Feelings dimension of TAS-20 were significantly<br> predictive of higher scores on SSI.<br> Conclusions: Alexithymia and low resilience were significant predictors of increased<br> suicide ideation in a first MD episode. However, study limitations must be considered<br> and future research needs are being discussed.
DOI: 10.5281/zenodo.5819128
title: Alexithymia, resilience, somatic sensations and their relationships with suicide ideation in drug naïve patients with first-episode major depression: An exploratory study in the "real world" everyday clinical practice

description: Alexithymia, resilience, somatic sensations and their<br> relationships with suicide ideation in drug naïve patients<br> with first-episode major depression: An exploratory study<br> in the “real world” everyday clinical practice Aim: The present study is aimed at revaluating alexithymia, somatic sensations, resilience<br> and their relationships with suicide ideation in drug naïve adult outpatients suffering<br> from first episode major depression (MD).<br> Methods: Data of 103 adult outpatients (49 men, 56 women) with a diagnostic and<br> statistical manual of mental disorders, 4th edition, text revision (DSM-IV-TR) diagnosis<br> of MD were analysed. Alexithymia was measured using the 20-item Toronto<br> Alexithymia Scale (TAS-20) and resilience with the 25 items Connor-Davidson Resilience<br> Scale (CD-RISC) whereas depression was evaluated using the 17-item Hamilton<br> Depression Rating Scale, somatic sensations with the Body Sensations Questionnaire<br> and suicide ideation with Scale of Suicide Ideation (SSI). Results: Gender comparisons between all demographic and clinical variables showed<br> no significant differences in all variables. Subjects who were found positive for<br> alexithymia showed higher scores on all clinical variables controlling for age, gender<br> and duration of the current episode. In a linear regression model, lower scores on<br> CD-RISC and Difficulty in Identifying Feelings dimension of TAS-20 were significantly<br> predictive of higher scores on SSI.<br> Conclusions: Alexithymia and low resilience were significant predictors of increased<br> suicide ideation in a first MD episode. However, study limitations must be considered<br> and future research needs are being discussed.
DOI: 10.6084/m9.figshare.17833028
title: Quality Assurance of a German COVID-19 Question Answering Systems using Component-based Microbenchmarking

description: Supplementary data for the paper "Quality Assurance of a German COVID-19 Question Answering Systems using Component-based Microbenchmarking" at the 15th ACM International WSDM Conference (WSDM 2022).<br>Abstract: Question Answering (QA) has become an often used method to retrieve data as part of chatbots and other natural-language user interfaces. In particular, QA systems of official institutions have high expectations regarding the answers computed by the system, as the provided information might be critical. In this demonstration, we use the official COVID-19 QA system that was developed together with the German Federal government to provide German citizens access to data regarding incident values, number of deaths, etc. To ensure high quality, a component-based approach was used that enables exchanging data between QA components using RDF and validating the functionality of the QA system using SPARQL. Here, we will demonstrate how our solution enables developers of QA systems to use a descriptive approach to validate the quality of their implementation before the system's deployment and also within a live environment.
DOI: 10.5281/zenodo.5819133
title: Religious Coping, Hopelessness, and Suicide Ideation in Subjects with First-EpisodeMajor Depression: An Exploratory Study in the RealWorld Clinical Practice

description: Religious Coping, Hopelessness, and Suicide Ideation<br> in Subjects with First-EpisodeMajor Depression:<br> An Exploratory Study in the RealWorld Clinical Practice Abstract: Background. This study aimed to evaluate the potential relationships between religious<br> coping, hopelessness, and suicide ideation in adult outpatients with the first episode of major<br> depressive disorder (MDD). Methods. Ninety-four adult outpatients with MDD were assessed<br> through the Hamilton Depression Rating Scale (HAM-D), the Beck Hopelessness Scale (BHS), and the<br> Scale of Suicide Ideation (SSI). Religious coping was assessed with the Italian version of the Brief<br> RCOPE scale, consisting of seven positive coping items (PosCop) and seven negative coping items<br> (NegCop). Results. The results showed that the Brief RCOPE PosCop scale exhibited a strong inverse<br> correlation with HAM-D, BHS, and SSI, whereas HAM-D and BHS were positively correlated with<br> SSI. Brief RCOPE NegCop scores were positively correlated only with SSI. Regression analysis with<br> SSI as the dependent variable showed that higher Brief RCOPE PosCop scores were associated with<br> lower suicide ideation, whereas higher HAM-D and BHS scores were associated with higher suicide<br> ideation. Conclusion. Positive religious coping may be a protective factor against the development of suicide ideation, perhaps counteracting the severity of depressive symptoms and hopelessness.<br> The evaluation of religious coping should be performed in all subjects with MDD in everyday clinical<br> practice. However, this study was preliminary, and limitations must be considered.
DOI: 10.5281/zenodo.5819132
title: Religious Coping, Hopelessness, and Suicide Ideation in Subjects with First-EpisodeMajor Depression: An Exploratory Study in the RealWorld Clinical Practice

description: Religious Coping, Hopelessness, and Suicide Ideation<br> in Subjects with First-EpisodeMajor Depression:<br> An Exploratory Study in the RealWorld Clinical Practice Abstract: Background. This study aimed to evaluate the potential relationships between religious<br> coping, hopelessness, and suicide ideation in adult outpatients with the first episode of major<br> depressive disorder (MDD). Methods. Ninety-four adult outpatients with MDD were assessed<br> through the Hamilton Depression Rating Scale (HAM-D), the Beck Hopelessness Scale (BHS), and the<br> Scale of Suicide Ideation (SSI). Religious coping was assessed with the Italian version of the Brief<br> RCOPE scale, consisting of seven positive coping items (PosCop) and seven negative coping items<br> (NegCop). Results. The results showed that the Brief RCOPE PosCop scale exhibited a strong inverse<br> correlation with HAM-D, BHS, and SSI, whereas HAM-D and BHS were positively correlated with<br> SSI. Brief RCOPE NegCop scores were positively correlated only with SSI. Regression analysis with<br> SSI as the dependent variable showed that higher Brief RCOPE PosCop scores were associated with<br> lower suicide ideation, whereas higher HAM-D and BHS scores were associated with higher suicide<br> ideation. Conclusion. Positive religious coping may be a protective factor against the development of suicide ideation, perhaps counteracting the severity of depressive symptoms and hopelessness.<br> The evaluation of religious coping should be performed in all subjects with MDD in everyday clinical<br> practice. However, this study was preliminary, and limitations must be considered.
DOI: 10.5281/zenodo.5819136
title: Alexithymia, suicide ideation, affective temperaments and homocysteine levels in drug naïve patients with post-traumatic stress disorder: an exploratory study in the everyday 'real world' clinical practice

description: Alexithymia, suicide ideation, affective<br> temperaments and homocysteine levels in drug<br> naïve patients with post-traumatic stress disorder:<br> an exploratory study in the everyday ‘real world’<br> clinical practice Objective: The present exploratory study aimed to investigate relationships between alexithymia, suicide<br> ideation, affective temperaments and homocysteine levels among drug-naïve adult outpatients with Post-<br> Traumatic Stress Disorder (PTSD) in an everyday ‘real world’ clinical setting.<br> Method: Sixty-four adult outpatients with PTSD were evaluated using the Davidson Trauma Scale (DTS),<br> the Toronto Alexithymia Scale (TAS–20), the Scale of Suicide Ideation (SSI), the Temperament Evaluation<br> of the Memphis, Pisa, Paris and San Diego-Autoquestionnaire. As well, homocysteine levels were<br> measured.<br> Results: Alexithymic subjects showed higher values on all scales but not homocysteine levels. Partial correlations<br> showed that almost all studied variables were correlated with each other, except homocysteine<br> levels. Regression analysis showed that higher disorder severity as measured by DTS and TAS-20<br> ‘Difficulty in Identifying Feelings’ dimension was associated with higher SSI scores.<br> Conclusions: In conclusion, alexithymic PTSD outpatients may be characterised by higher disorder severity<br> and difficulty in identifying feelings that may be linked to increased suicide ideation, regardless of<br> affective temperaments or homocysteine levels. Homocysteine levels were not related to any studied variable.<br> However, study limitations are discussed and must be considered.
DOI: 10.5281/zenodo.5819135
title: Alexithymia, suicide ideation, affective temperaments and homocysteine levels in drug naïve patients with post-traumatic stress disorder: an exploratory study in the everyday 'real world' clinical practice

description: Alexithymia, suicide ideation, affective<br> temperaments and homocysteine levels in drug<br> naïve patients with post-traumatic stress disorder:<br> an exploratory study in the everyday ‘real world’<br> clinical practice Objective: The present exploratory study aimed to investigate relationships between alexithymia, suicide<br> ideation, affective temperaments and homocysteine levels among drug-naïve adult outpatients with Post-<br> Traumatic Stress Disorder (PTSD) in an everyday ‘real world’ clinical setting.<br> Method: Sixty-four adult outpatients with PTSD were evaluated using the Davidson Trauma Scale (DTS),<br> the Toronto Alexithymia Scale (TAS–20), the Scale of Suicide Ideation (SSI), the Temperament Evaluation<br> of the Memphis, Pisa, Paris and San Diego-Autoquestionnaire. As well, homocysteine levels were<br> measured.<br> Results: Alexithymic subjects showed higher values on all scales but not homocysteine levels. Partial correlations<br> showed that almost all studied variables were correlated with each other, except homocysteine<br> levels. Regression analysis showed that higher disorder severity as measured by DTS and TAS-20<br> ‘Difficulty in Identifying Feelings’ dimension was associated with higher SSI scores.<br> Conclusions: In conclusion, alexithymic PTSD outpatients may be characterised by higher disorder severity<br> and difficulty in identifying feelings that may be linked to increased suicide ideation, regardless of<br> affective temperaments or homocysteine levels. Homocysteine levels were not related to any studied variable.<br> However, study limitations are discussed and must be considered.
DOI: 10.5281/zenodo.5819138
title: Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a ''real-world'' chart review study

description: Adjunctive vortioxetine for SSRI-resistant major<br> depressive disorder: a ‘‘real-world’’ chart review study Objective: Selective serotonin reuptake inhibitors (SSRIs) are the cornerstone of treatment of major<br> depressive disorder (MDD). However, non-response is common, often necessitating combination<br> strategies. The present study assessed the efficacy of vortioxetine as an add-on therapy in patients<br> with SSRI-resistant MDD.<br> Methods: The charts of 36 adult outpatients with DSM-IV-TR MDD who had not achieved a response<br> after at least 8 weeks of treatment with an SSRI were reviewed retrospectively. Subjects were treated<br> with vortioxetine (5-20 mg/day) for 8 weeks added to the current SSRI. The main outcome measures<br> were change from baseline in total Hamilton Scale for Depression (HAM-D) score and the rate of<br> response (a 50% or greater reduction in HAM-D score and a Clinical Global Impression - Improvement<br> module [CGI-I] score of 1 or 2 at endpoint). HAM-D scores p 7 were considered as remission.<br> Additional outcome measures included the Snaith-Hamilton Pleasure Scale (SHAPS) and the Scale<br> for Suicide Ideation (SSI).<br> Results: 32 patients completed the 8 weeks of treatment. At 8 weeks, a significant reduction in HAM-D<br> score was observed (p p 0.001), with response obtained by 41.7% and remission by 33.3% of<br> patients. Significant reductions in SHAPS and SSI were also observed (p p 0.001 for both scales).<br> Conclusions: Adjunctive vortioxetine may be useful and well-tolerated in stage I treatment-resistant<br> depression. However, the limitations of this study (such as small sample size, absence of<br> randomization and control group, retrospective design, etc.) must be considered.
DOI: 10.5281/zenodo.5819137
title: Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a ''real-world'' chart review study

description: Adjunctive vortioxetine for SSRI-resistant major<br> depressive disorder: a ‘‘real-world’’ chart review study Objective: Selective serotonin reuptake inhibitors (SSRIs) are the cornerstone of treatment of major<br> depressive disorder (MDD). However, non-response is common, often necessitating combination<br> strategies. The present study assessed the efficacy of vortioxetine as an add-on therapy in patients<br> with SSRI-resistant MDD.<br> Methods: The charts of 36 adult outpatients with DSM-IV-TR MDD who had not achieved a response<br> after at least 8 weeks of treatment with an SSRI were reviewed retrospectively. Subjects were treated<br> with vortioxetine (5-20 mg/day) for 8 weeks added to the current SSRI. The main outcome measures<br> were change from baseline in total Hamilton Scale for Depression (HAM-D) score and the rate of<br> response (a 50% or greater reduction in HAM-D score and a Clinical Global Impression - Improvement<br> module [CGI-I] score of 1 or 2 at endpoint). HAM-D scores p 7 were considered as remission.<br> Additional outcome measures included the Snaith-Hamilton Pleasure Scale (SHAPS) and the Scale<br> for Suicide Ideation (SSI).<br> Results: 32 patients completed the 8 weeks of treatment. At 8 weeks, a significant reduction in HAM-D<br> score was observed (p p 0.001), with response obtained by 41.7% and remission by 33.3% of<br> patients. Significant reductions in SHAPS and SSI were also observed (p p 0.001 for both scales).<br> Conclusions: Adjunctive vortioxetine may be useful and well-tolerated in stage I treatment-resistant<br> depression. However, the limitations of this study (such as small sample size, absence of<br> randomization and control group, retrospective design, etc.) must be considered.
DOI: 10.25345/c5s571
title: MassIVE MSV000088639 - Dysferlin deficient mice proteomics
title: Investigation of age-dependent changes in the proteomic profile of Dysferlin-deficient mouse skeletal muscle relative to healthy muscle.
DOI: 10.5281/zenodo.5819140
title: Efficacy of bio- and neurofeedback for depression: a meta-analysis

description: Efficacy of bio- and neurofeedback for<br> depression: a meta-analysis Background. For many years, biofeedback and neurofeedback have been implemented in the<br> treatment of depression. However, the effectiveness of these techniques on depressive symptomatology<br> is still controversial. Hence, we conducted a meta-analysis of studies extracted<br> from PubMed, Scopus, Web of Science and Embase.<br> Methods. Two different strings were considered for each of the two objectives of the study:<br> A first group comprising studies patients with major depressive disorder (MDD) and a second<br> group including studies targeting depressive symptomatology reduction in other mental or<br> medical conditions.<br> Results. In the first group of studies including patients with MDD, the within-group analyses<br> yielded an effect size of Hedges’ g = 0.717, while the between-group analysis an effect size of<br> Hedges’ g = 1.050. Moderator analyses indicate that treatment efficacy is only significant when<br> accounting for experimental design, in favor of randomized controlled trials (RCTs) in comparison<br> to non RCTs, whereas the type of neurofeedback, trial design, year of publication,<br> number of sessions, age, sex and quality of study did not influence treatment efficacy. In<br> the second group of studies, a small but significant effect between groups was found<br> (Hedges’ g = 0.303) in favor of bio- and neurofeedback against control groups. Moderator analyses<br> revealed that treatment efficacy was not moderated by any of the sociodemographic and<br> clinical variables.<br> Conclusions. Heart rate variability (HRV) biofeedback and neurofeedback are associated with<br> a reduction in self-reported depression. Despite the fact that the field has still a large room for<br> improvement in terms of research quality, the results presented in this study suggests that both<br> modalities may become relevant complementary strategies for the treatment of MDD and<br> depressive symptomatology in the coming years.